Is ferric citrate non-inferior to sevelamer to lower protein uremic toxins in pre-dialysis CKD with hyperphosphatemia? Protein-bound uremic toxin Sevelamer Ferric citrate Chronic kidney disease
Conditions
Interventions
Ferric citrate group: (500 mg/tab)
Patients with serum phosphate 4.5-4.9 mg/dL, will receive Ferric citrate 1000 mg after each meal, three times daily. Total 3000 mg per day.
Patients with serum phosp
Active Comparator Drug,Placebo Comparator Drug
Ferric citrate,Sevelamer
Sponsors
Thai Red Cross Society Research Fund
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria 1. Adult (age 18-80 years) 2. Pre-dialysis CKD eGFR less than 60 ml/min/1.73m2 by CKD-EPI creatinine equation 3. Hyperphosphatemia (Serum phosphate more than 4.5 mg/dL) without phosphate-binding agents or after 1 week washout
Exclusion criteria
Exclusion criteria: 1. Received sevelamer before 2. Serum ferritin more than 800 ng/mL or TSAT more than 40% 3. Hemochromatosis 4. Pregnancy 5. History of gastrointestinal bleeding in 6 months 6. Previous antibiotic use in 2 weeks 7. Previous biotic supplement in 2 weeks 8. Previous IV or oral iron supplement in 2 weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| P-cresyl sulfate 1 month responder rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Indoxyl sulfate, Fibroblast growth factor23 1 month level | — |
Countries
Thailand
Contacts
Public ContactWannee Jiamjaipaiboon
King Chulalongkorn Memorial Hospital
Outcome results
None listed